Show simple item record

dc.contributor.authorTabatabai, A.
dc.contributor.authorRabin, J.
dc.contributor.authorMenaker, J.
dc.contributor.authorMadathil, R.
dc.contributor.authorGalvagno, S.
dc.contributor.authorMenne, A.
dc.contributor.authorChow, J.H.
dc.contributor.authorHerr, D.
dc.contributor.authorTanaka, K.
dc.contributor.authorScalea, T.
dc.contributor.authorMazzeffi, M.
dc.date.accessioned2020-06-30T18:46:31Z
dc.date.available2020-06-30T18:46:31Z
dc.date.issued2020
dc.identifier.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85086621687&doi=10.1213%2fXAA.0000000000001236&partnerID=40&md5=42f6aa9cc1ef067ff24119f1152b1a55
dc.identifier.urihttp://hdl.handle.net/10713/13204
dc.description.abstractCritically ill patients with coronavirus disease 2019 (COVID-19) have been observed to be hypercoagulable, but the mechanisms for this remain poorly described. Factor VIII is a procoagulant factor that increases during inflammation and is cleaved by activated protein C. To our knowledge, there is only 1 prior study of factor VIII and functional protein C activity in critically ill patients with COVID-19. Here, we present a case series of 10 critically ill patients with COVID-19 who had severe elevations in factor VIII activity and low normal functional protein C activity, which may have contributed to hypercoagulability.en_US
dc.description.urihttps://doi.org/10.1213/XAA.0000000000001236en_US
dc.language.isoen_USen_US
dc.publisherWolters Kluwer Healthen_US
dc.relation.ispartofA&A practice
dc.subject.lcshCOVID-19 (Disease)en_US
dc.subject.meshFactor VIIIen_US
dc.subject.meshProtein Cen_US
dc.subject.meshThrombophiliaen_US
dc.titleFactor VIII and Functional Protein C Activity in Critically Ill Patients With Coronavirus Disease 2019: A Case Seriesen_US
dc.typeArticleen_US
dc.identifier.doi10.1213/XAA.0000000000001236
dc.identifier.pmid32539272


This item appears in the following Collection(s)

Show simple item record